600196 Shanghai Fosun Pharmaceutical
- 23.38
- +0.24+1.04%
Shanghai Fosun Pharmaceutical News
HTSC: Different performance for beauty and medical beauty in Q2. Q3 may be more challenging for new product sales during off-season.
In Q3 24, it is the off-season for the industry, but also an important window period for many brand manufacturers to prepare for the November 11 shopping festival. It is recommended to pay close attention to new product developments.
Hong Kong stock concept tracking| The surgical robot industry is developing rapidly, and institutions are paying attention to investment opportunities brought by updates to medical devices (attached with concept stocks).
The global surgical robot market is expected to reach $28.51 billion by 2025, with a compound annual growth rate of 27.1% from 2021 to 2025.
Fosun Pharma Announces Merger Delay
Fosun Pharma Receives Offers for Share Alternative Offer Related to Henlius Merger Offer
Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) received offers for a potential share alternative offer in relation to its merger offer for Shanghai Henlius Biotech (HKG:2696),
BofA Merrill Lynch is bullish! Raised the target price of Fosun Pharma's (02196) H shares to 17 yuan, accelerating innovation and transformation to achieve results.
Recently, international investment bank Morgan Stanley released its latest research report and raised the target price for Fosun Pharma's H shares from the original HKD 16 to HKD 17, indicating a potential increase of over 25% from the current H share price. It also maintained a 'shareholding' rating for Fosun Pharma, and predicted that the compound annual growth rates of the company's pharmaceutical, equipment, and hospital businesses' revenue from 2023 to 2025 will reach 8%, 13%, and 10%, respectively. This forecast reflects the strong growth momentum of core pharmaceutical sales, particularly in biosimilars and innovative drugs.
Fosun Pharma Advances Towards Henlius Privatization
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Fosun Pharma (02196) spent approximately 10.6336 million yuan to buy back 0.482 million A shares on July 9.
Fosun Pharma (02196) announced that it will invest approximately 10.6336 million yuan (RMB) on July 9, 2024...
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Golden Stock Announcement | Gogox Speed-W achieved a total package volume of 5.9834 billion pieces in the second quarter, a year-on-year increase of 30.7%.
Important Announcement: Baifang Stock (06657) priced at a minimum of HKD 36 for public offering and received 6.58 times subscription. Shanghai Pharma (02607): Citrate tofacitinib active pharmaceutical ingredient gets marketing approval. Fosun Pharma (02196): Registration approval for the addition therapy with Levetiracetam extended-release tablets for partial-onset seizures in patients aged 12 and above. CIRC (01763): Success in signing the overall supply project of nuclear medical equipment in Nigeria. Share buyback/sell-off: Tencent (00700) spent HKD 1.004 billion to repurchase 2.65 million shares of Meituan-W.
Shanghai Fosun Pharmaceutical (Group) Cancer Treatment Gets NMPA's Nod for Clinical Trials
Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) said China's National Medical Products Administration (NMPA) approved the commencement of the Phase Ib/II clinical trial in China for FH-20
Shanghai Fosun Pharmaceutical Unit Gets Marketing Approval for Epilepsy Drug in China
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Hunan Dongting Pharmaceutical recently received marketing registration approval for its Levetiracetam sustained-release tablets from China's N
Fosun Pharma Subsidiary Gains Drug Approval
Fosun Pharma Advances Cancer Treatment Trial
Fosun Pharma (02196): The application for marketing approval of lacosamide extended-release tablets for add-on therapy for partial seizures in patients aged 12 years and older has been approved.
Fosun Pharma (02196) announced that its subsidiary, Hunan Dongting Pharmaceutical Co., Ltd., independently developed...
Express News | Shanghai Fosun Pharma - Unit Got Approval From Nmpa of China for Clinical Trial of Fh-2001 Capsule Combined With Serplulimab Injection
Express News | Shanghai Fosun Pharma - Unit Got Marketing Registration Approval for Levetiracetam Sustained-Release Tablets From Nmpa China
Fosun Pharma (600196.SH): Clinical trial of FH-2001 capsules combined with Sulli monoclonal injection for the treatment of advanced solid tumors has been approved.
On July 8th, Gelon Hui announced that its subsidiary Fosun Pharma (600196.SH) received approval from the National Medical Products Administration to conduct clinical trials of FH-2001 capsule combined with Sruply monoclonal antibody injection for the treatment of advanced solid tumors. After meeting the requirements, Xingcheng Xinhui plans to conduct phase Ib/II clinical trials of this treatment in mainland China (excluding Hong Kong, Macao and Taiwan). The FH-2001 capsule involved in this treatment program is a VEGFR/FGFR dual-mechanism small molecule inhibitor and a PD-L1 regulator independently developed by the group, and is intended to be the main focus.
Fosun Pharma (600196.SH): Lacosamide extended-release tablets receive pharmaceutical registration approval.
Fosun Pharma (600196.SH) announced that the application for registration and approval of the listing of Levetiracetam Extended-Release Tablets developed independently by its holding subsidiary Hunan Dongting Pharmaceutical Co., Ltd. for adjunctive therapy of partial-onset seizures in patients 12 years of age and older has been approved by the National Medical Products Administration.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Analysis
Price Target
No Data
